A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of TX000045 After 24 Weeks of Treatment in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (PH-HFpEF)
-
Enrollment
This study is not currently enrolling. -
Research Area
Heart, Lung and Vascular Research -
Principal Investigator
-
Sponsor
Tectonic Therapeutic
The study Sponsor is developing the investigational (experimental) drug TX000045 as a potential new treatment for patients with high lung blood pressure due to heart failure.